Latest 8-K filings

F&M Bank Corp. completed a restructuring of its available-for-sale securities portfolio, utilizing a one-time gain from an investment sale to acquire higher-yielding assets.

Ohio Valley Banc Corp. announced its board of directors has declared a quarterly cash dividend of $0.25 per share.

Bion Environmental Technologies, Inc. has reached a settlement agreement with Hamstra Builders, Inc. to resolve all litigation and mechanics liens related to the construction of its Fair Oaks demonstration facility.

Trex Company, Inc. clarified its full-year Adjusted EBITDA guidance after an incorrect figure was mentioned during a conference call.

JPMorgan Chase & Co. announced robust second-quarter 2026 financial results, driven by strong revenue growth across its business segments and effective expense management.

Catalyst Bancorp, Inc. has successfully acquired Lakeside Bancshares, Inc. and its subsidiary Lakeside Bank for $41.1 million, expanding its assets and branch network.

Citigroup Inc. announced robust second quarter 2026 financial results, with net income soaring 45% year-over-year to $5.8 billion on revenues of $24.8 billion.

Genprex, Inc. files an 8-K detailing a 1-for-22 reverse stock split effective July 16, 2026, and provides updates on its Acclaim-1 and Acclaim-3 clinical trials.

Ligand Pharmaceuticals has finalized its acquisition of XOMA Royalty Corporation for approximately $739 million, significantly expanding its biopharmaceutical royalty asset portfolio.

America's Car-Mart announced its fourth quarter and full fiscal year 2026 results, highlighting significant revenue declines, increased net charge-offs, and ongoing strategic and financing reviews.

Central Plains Bancshares, Inc. reports a new three-year change in control agreement for its Executive Vice President and Chief Financial Officer, Bradley M. Kool, effective July 8, 2026.

Ligand Pharmaceuticals Incorporated has finalized its acquisition of XOMA Royalty Corporation, with XOMA Royalty stockholders receiving $39.00 per share in cash and a Contingent Value Right.

SUI Group Holdings Limited announced the resignation of its Chief Investment Officer, Stephen Mackintosh, effective July 8, 2026, with the Chairman to manage the transition.

Splash Beverage Group announced settlements with creditors reducing $3.3 million in liabilities to $550,000 and approved a 1-for-4 reverse stock split to aid NYSE American compliance.

California Resources Corporation provided preliminary, unaudited realized price data and commodity derivative activity for the three months ended June 30, 2026.

flyExclusive has finalized its acquisition of Jet.AI's aviation assets, integrating customers, aircraft, future delivery positions, and financial assets to accelerate fleet growth and enhance capital flexibility.

First Bancorp announced its definitive agreement to acquire First Carolina Bancshares Corporation for approximately $166 million in a stock and cash transaction, aiming to expand its South Carolina presence.

Holley Inc. has made an additional $15 million voluntary prepayment of debt, bringing its total debt reduction to $115 million since September 2023, funded entirely by free cash flow.

SS Innovations International, Inc. announced the appointment of Sarah M. Romano as its new Chief Financial Officer, effective August 3, 2026, bringing extensive public company and capital markets experience.

Syndax Pharmaceuticals announced updates on its late-stage programs and introduced new pipeline assets, including novel inhibitors for NSCLC and myelofibrosis, during its R&D event.

Runway Growth Finance Corp. announces Q2 2026 portfolio activity, including $85.8 million in new fundings, and a capital allocation strategy prioritizing share repurchases to address a perceived discount to Net Asset Value.

Diodes Incorporated announced a definitive agreement to acquire ElevATE Semiconductor, Inc. for $250 million in an all-cash transaction to expand its analog and mixed-signal portfolio.

VYNE Therapeutics and Yarrow Bioscience have released an investor presentation detailing their proposed merger and Yarrow's lead drug candidate, YB-101, for Graves' Disease and Thyroid Eye Disease.

Inhibikase Therapeutics announced the sale of $50 million in common stock through its at-the-market facility to RA Capital Management.

Fastenal Company announced a 14.7% increase in daily sales for the second quarter of 2026, driven by key customer wins and pricing strategies, while maintaining operating margin.

Immunic, Inc. released an updated presentation on July 14, 2026, detailing its development programs, clinical trial progress, and future outlook.

RE/MAX Holdings, Inc. announces early termination of HSR Act waiting period for its merger with The Real Brokerage Inc., advancing the transaction.

Cingulate Inc. announced key stockholder approvals at its 2026 Annual Meeting, including an amendment to its equity incentive plan and changes to its Board of Directors structure.

Virtu Financial provides preliminary Q2 2026 results, anticipating $285 million in net income, and announces plans to upsize its term loans by $400 million.

Valion Bio reports progress in its Entolimod program, focusing on biodefense preparedness, domestic manufacturing scale-up, and oncology expansion.